|
[이데일리 김호준 기자] The background is drawing attention as it is known that there was full support from Samsung Group to’Punglim Pharmatech’, a domestic medical device company that developed the minimum residual dose (LDV) syringe for corona 19 vaccination. The Samsung Group is evaluated for playing the role of a hidden’long leg uncle’ by mobilizing all of its affiliates, including Samsung Electronics and Samsung Bioepis, to support from mass production of vaccine syringes to approval by the US Food and Drug Administration (FDA).
President Moon Jae-in said on the 18th that Poonglim Pharmatech’s LDV syringe was approved by the US FDA, “Samsung Bioepis, along with the Ministry of Food and Drug Safety, was very helpful for this FDA certification.” Thank you for doing it.”
Previously, Poonglim Pharmatech received FDA approval for LDV syringe products on the 17th. Poonglim’s LDV syringe minimizes the amount of vaccine left in the syringe when the drug is administered. The remaining amount of injection per serving (person) is 84 microliters (μL) or more for a general syringe, but 25 μL or less for an LDV syringe. In particular, Poonglim Pharmatech’s LDV syringe reduced it to 4 μL. With a regular syringe, you can only inoculate up to 5 doses per bottle of corona vaccine, but with Poonglim’s LDV syringe, you can do more than 6 doses per bottle.
In particular, Poonglim Pharmatech’s syringe is equipped with a safety guard function to prevent stab accidents and the injection residual capacity required by overseas corona vaccine companies such as Pfizer. Vaccine companies paid attention to this point and tried to see if it could supply syringes to Poonglim Pharmatech. With this FDA approval, Poonglim Pharmatech can supply syringes to several overseas vaccine companies, including Pfizer.
It is known that medical devices usually need a period of at least three months to obtain FDA approval, but the industry explained that this FDA approval was able to come out sooner than expected because Samsung Biologics and Samsung Bioepis fully supported Poonglim Pharmatech. Poonglim Pharmatech requested the FDA to approve the use of syringe products on the 18th of last month.
Samsung Electronics, which succeeded in mass production last year by supporting a smart factory to a mask and diagnostic kit company, also rolled up its arms. Since the end of December last year, Samsung Electronics has supported Poonglim Pharmatech’s production of prototype molds for syringe production through its partner factories in Gumi and Gwangju, and completed this within 4 days of the year-end holiday period. About 30 Samsung Electronics’ manufacturing experts dispatched to Poonglim Pharmatech helped streamline the entire production process from order receipt to shipment, from syringe injection productivity to automated assembly, raw material classification management, and logistics optimization.
It is known that Samsung also played a big role in finding a company called Poonglim Pharmatech and preparing for the increase in demand for syringes. President Moon explained, “Samsung first predicted that the demand for minimal residual syringes will increase, and by acknowledging Poonglim Pharmatech’s technological prowess, it led the mass production of excellent products through all-round cooperation, such as supporting automation of production lines and mold technology.”
An official from the SMEs said, “I know that Samsung applied without expecting a separate price for the national interest.”
|
